Digital Transformation and Sustainability Evangelist Vijay Sethi Joins the Advisory Board of Cyble
11.5.2021 11:42:00 EEST | Business Wire | Press release
Cyble, an AI-powered, Y Combinator-backed, cyber intelligence company that empowers organizations with darkweb/cybercrime monitoring and mitigation services, today announced the addition of eminent technology and sustainability evangelist Vijay Sethi to its Advisory Board. Vijay has rich experience in advising and mentoring corporates and startups in various facets of management, digital transformation, and sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005525/en/
Digital Transformation and Sustainability Evangelist Vijay Sethi Joins the Advisory Board of Cyble (Photo: Business Wire)
“A key member of our Advisory Board, Vijay’s insights will help steer our strategic development initiatives. His appointment is in line with Cyble’s commitment to achieving our goals by ensuring sustained growth, maintaining operational excellence, establishing a culture of innovation, and raising the standards for corporate governance. As Cyble continues to deliver advanced threat intelligence to its end-clients, I look forward to working with Vijay as Cyble continues to grow and span across uncharted territories,” says Manish Chachada, COO and Co-founder of Cyble.
An industry veteran with over 30 years of experience, Vijay Sethi has served as the CIO, CHRO, and Head CSR at Hero MotoCorp. Prior to that, he worked with Ranbaxy and Tata Consultancy Services. A huge proponent of digital technologies like the Cloud, Mobility, Artificial Intelligence, RPA, AR, VR, and cybersecurity and risk management, he has experience in digital transformation roadmap and project development ventures, large-scale IT projects, community development programs, and talent development and employee engagement campaigns.
Commenting on joining forces with Cyble, Vijay says, “I strongly endorse the growing need to make the digital world safer and help share cybersecurity insights and threat intelligence with consumers. The team at Cyble, their technological offerings, and the company’s commitment to keeping customers and users safe are impressive. I’m very pleased to be joining Cyble as an Advisor and look forward to working with its talented and dynamic teams.”
Rated among India’s Best IT leaders, over the years, Vijay has won several prestigious recognitions, including CIO of the year many times, CIO Hall of Fame, Super League CIO, Champion CIO, Global CIO, Global CIO Hall of fame, Digital Icon of India, India’s Best IT manager, India’s Most Innovative CSR Leader, and many others. He also serves as the Chairman of SAP India User Group (INDUS). Earlier, he also served as the Chairman of the IT Committee of Society of the Indian Automobile Manufacturers (SIAM) and the Chairman of CSR Committee of SIAM. Over the years, Vijay has also been a member of various Committees of CII and FICCI.
Beenu Arora, CEO and Founder of Cyble, says, “I am delighted to welcome Vijay into the board. He truly needs no introduction in the cybersecurity fraternity, and his problem-solving skills and passion for building efficient solutions make him best suited to take Cyble to the next level. His appointment has been a significant step in our effort to nurture our world-class business leadership team. Vijay’s actionable counsel will prove beneficial in shaping Cyble’s strategic business decisions.”
About Cyble:
Cyble is a global threat intelligence SaaS provider that helps enterprises protect themselves from cybercrimes and exposure in the Darkweb. Its prime focus is to provide organizations with real-time visibility to their digital risk footprint. Backed by Y Combinator as part of the 2021 winter cohort, Cyble has also been recognized by Forbes as one of the top 20 Best Cybersecurity Start-ups To Watch In 2020. Headquartered in Alpharetta, Georgia, and with offices in Australia, Singapore, and India, Cyble has a global presence. To learn more about Cyble, visit www.cyble.io.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005525/en/
Contact information
Medha Roy Chowdhury
EMAIL:
Enquiries@Cyble.io
MOBILE: +1 678 379 3241
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom